Filtered By:
Drug: Avastin
Education: Conferences
This page shows you your search results in order of date.
Order by Relevance | Date
Total 29 results found since Jan 2013.
First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis
CONCLUSION: For NSCLC patients with EGFR Leu858Arg mutations, the second-generation TKIs, the third-generation TKIs, and the combined treatments showed better efficacy than the first-generation TKIs for PFS. There were, however, no significant differences between each group for OS.PMID:36274751 | PMC:PMC9580106 | DOI:10.1177/20406223221125706
Source: Adv Data - October 24, 2022 Category: Epidemiology Authors: Chongxiang Chen Chunning Zhang Huaming Lin Qianyin Liu Limian Wu Chengzhi Zhou Jiexia Zhang Source Type: research
Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis
Clin Exp Med. 2022 Sep 24. doi: 10.1007/s10238-022-00894-1. Online ahead of print.ABSTRACTNeoadjuvant treatment options for triple-negative breast cancer (TNBC) are abundant, but the efficacy of different combinations of treatment options remains unclear. Our network meta-analysis aimed to evaluate the effectiveness and safety of various neoadjuvant treatment options in patients with TNBC. Literature reports published before March 31, 2022, were retrieved from the PubMed, Embase, Cochrane Library, main oncology conference of the European Society of Medical Oncology, American Society of Clinical Oncology, and San Antonio Br...
Source: Clinical Breast Cancer - September 24, 2022 Category: Cancer & Oncology Authors: Jinming Li Guoshuang Shen Miaozhou Wang Xingfa Huo Fuxing Zhao Dengfeng Ren Yi Zhao Jiuda Zhao Source Type: research
Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer
CONCLUSIONS: Weekly paclitaxel combined with carboplatin for first-line treatment of epithelial ovarian cancer likely improves PFS slightly (moderate-certainty evidence) but not OS (high-certainty evidence), compared to tri-weekly paclitaxel combined with carboplatin. However, this was associated with increased risk for high-grade anaemia, treatment discontinuation, dose delays and dose omissions (high- to low-certainty evidence). Our findings may not apply to women receiving bevacizumab in first-line therapy, those receiving treatment in the neo-adjuvant setting, or those with rare subtypes of clear cell or mucinous ovari...
Source: Cochrane Database of Systematic Reviews - February 21, 2022 Category: General Medicine Authors: Natalie Yl Ngoi Nicholas Lx Syn Robby M Goh Boon Cher Goh Ruby Yun-Ju Huang Yu Yang Soon Elizabeth James Adrian Cook Andrew Clamp David Sp Tan Source Type: research
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
CONCLUSIONS: Authors' conclusions The evidence in this review suggests that single-agent ICI in people with NSCLC and PD-L1 ≥50% probably leads to a higher overall survival rate and may lead to a higher progression-free survival and overall response rate when compared to platinum-based chemotherapy and may also lead to a lower rate of adverse events and higher HRQoL. Combined ICI in people with NSCLC and PD-L1 ≥50% also probably leads to a higher overall survival rate when compared to platinum-based chemotherapy, but its effect on progression-free survival, overall response rate and HRQoL is unknown due to a lack of da...
Source: Cochrane Database of Systematic Reviews - April 30, 2021 Category: General Medicine Authors: Roberto Ferrara Martina Imbimbo Reem Malouf Sophie Paget-Bailly Fran çois Calais Corynne Marchal Virginie Westeel Source Type: research
R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis
CONCLUSION: The addition of another drug to frontline R-CHOP treatment for DLBCL did not result in a significant improvement in OS, although we did observe improved disease control compared to R-CHOP, perhaps most evident with the addition of lenalidomide. Yet, RCHOP + X was associated with an increased risk for serious and hematological adverse events. Further studies could reveal subgroups that would benefit most from augmentation of standard R-CHOP.PMID:33734921 | DOI:10.1080/0284186X.2021.1898048
Source: Acta Oncologica - March 18, 2021 Category: Cancer & Oncology Authors: Oren Pasvolsky Alon Rozental Pia Raanani Anat Gafter-Gvili Ronit Gurion Source Type: research
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
CONCLUSIONS: Authors' conclusions The evidence in this review suggests that single-agent ICI in people with NSCLC and PD-L1 ≥50% probably leads to a higher overall survival rate and may lead to a higher progression-free survival and overall response rate when compared to platinum-based chemotherapy and may also lead to a lower rate of adverse events and higher HRQoL. Combined ICI in people with NSCLC and PD-L1 ≥50% also probably leads to a higher overall survival rate when compared to platinum-based chemotherapy, but its effect on progression-free survival, overall response rate and HRQoL is unknown due to a lack of da...
Source: Cochrane Database of Systematic Reviews - December 14, 2020 Category: General Medicine Authors: Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V Tags: Cochrane Database Syst Rev Source Type: research
Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
CONCLUSIONS: We found that, at one year, monthly regimens are probably more effective than PRN regimens using seven or eight injections in the first year, but the difference is small and clinically insignificant. Endophthalmitis is probably more common with monthly injections and differences in costs between regimens are higher if aflibercept or ranibizumab are used compared to bevacizumab. This evidence only applies to settings in which regimens are implemented as described in the trials, whereas undertreatment is likely to be common in real-world settings. There are no data from RCTs on long-term effects of different tre...
Source: Cochrane Database of Systematic Reviews - May 4, 2020 Category: General Medicine Authors: Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G Tags: Cochrane Database Syst Rev Source Type: research
